Navigation Links
A New Era in Cell Biology: German Company Develops Groundbreaking Alternative to Stem Cell Therapy
Date:3/5/2008

KIEL, Germany, March 5 /PRNewswire/ -- In mid-March the German Bundestag (Lower House) is due to vote on an amendment to the German Stem Cell Act. The opposing poles in the debate on embryonic stem cell research could not be further apart: its proponents are calling for the complete liberalisation of stem cell research, while its critics are in favour of a general ban on the use of human stem cells, which are produced from embryos. While the Bundestag debates on a new regulation, Blasticon Biotechnologische Forschung GmbH has made a breakthrough in cell biology:

Blasticon has at its disposal a patented technology based on which monocytes (mature white blood cells) from blood extracted from veins can be turned into cells with programmable properties comparable to those of stem cells and differentiated into different functional cells for diverse applications in diagnostics and therapy.

Cellular quick-change artists in the fight against widespread diseases

"We work with mononuclear cells, which can simply be extracted from blood," says Prof. Dr. med. Fred Fandrich, Director of the Clinic for General Surgery and Thoracic Surgery at the University Clinic of Schleswig-Holstein, Kiel, and founder of the company. "In the second step of our patented procedure we can 'reprogram' these programmable cells into the desired target cells, for example liver or muscle cells or cells in pancreatic islets of Langerhans." The therapeutic possibilities lie in replacing defective or missing cells (regenerative medicine) or producing cells that regulate the immune system. A significant advancement in the treatment of autoimmune diseases or for transplant medicine.

The "reprogrammed" cells can be used both as diagnostic agents or for therapeutic purposes. Inflammatory bowel diseases (Morbus Crohn, Colitis ulcerosa), diabetes, rheumatism, cardiac infarction, liver diseases and kidney and liver transplants, among others, are among the main therapeutic areas. Blasticon's therapeutic agents are for the most part in advanced stages of preclinical or clinical phases of development. In most cases, the medical fields of application described necessitate costly lifelong treatment. Blasticon's reprogrammed cells make it possible to attack illnesses at their origin and to prevent long duration of treatment. A further possible positive effect of the technologies is significant cost-reduction in the health system.

Products which are ready for application and soon to be introduced onto the market

The diagnostic application of the in vitro acute toxicity test "NeoHeps" can be introduced onto the market as soon as NeoHelps has been successfully validated by the European Union (EU). The REACH programme, a new EU chemical regulation that came into force on 1 June 2007 is of particular importance here; it will in future oblige all manufacturers, importers and users of chemicals to evaluate their substances as being safe. This presents a great challenge to many industries, whether they produce shampoos, kitchen utensils, computers, televisions, furniture or clothing - owing to the implementation of REACH, over 30,000 known chemicals are to be retested for their toxic safety. New chemical entities must also be tested with the REACH test regime. According to estimates, around 3,500 tests a year will be necessary.

Up to now, Blasticon's "NeoHeps" test system has passed all necessary tests within the EU test framework and has therefore been able to secure itself a clear market lead. In addition, "NeoHeps" could be of considerable benefit to the pharmaceutical industry, for example in examining the effectiveness and undesirable side effects of medicines. The advantages are less animal testing, unlimited availability of the required cells and cost-reduction in the area of drug development.

Prof. Dr. med Fandrich comments on the current political debate: "Personally, I do not think much of the use of embryonic cells for clinical application. Pure research and clinical research should be kept separate from one another. Embryonic stem cells are necessary so that we can gain a better understanding of the programmability of cells."

About Blasticon Biotechnologische Forschung GmbH

Blasticon is a biotechnology company that is active in the fields of cellular medicine and in vitro diagnostics. Blasticon has at its disposal a patented technology that enables it to turn monocytes (mature white blood cells) from extracted blood into PCMO (programmable cells of monocytic origin = stem-cell-like human cells) and to differentiate them into different functional cells for diverse applications in diagnostics and therapy. The company was founded in 2002.

Contact:

PRint Agentur fur Offentlichkeitsarbeit GmbH

Katja Schmidt

Ottobrunner Strasse 26

82008 Unterhaching

Germany

Telephone: +49-89-66532-1280

Telefax: +49-89-66532-1115

Email: katja.schmidt@heye.de


'/>"/>
SOURCE Blasticon Biotechnologische Forschung GmbH
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Germany Hosts World Leading Medical Industry Fair
2. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
3. Spectral partner launches EAA(TM) Rapid Sepsis Diagnostic in Germany
4. ROBODOC(R) Emerges as a Curexo Technology Company at Upcoming Orthopaedic Surgeons Conference in San Francisco
5. Stem Cell Company t2cure Appoints Dr Rueck Head of Clinical Operations
6. National Stem Cell Holding, Inc. Has Engaged BMA Securities to Assist and Advise the Company With Its Current Capital Raise of $3,500,000
7. European Company NovaSecta Joins First Chinese CRO Service Alliance for Drug Discovery Solutions
8. Nastech Pharmaceutical Company Implements Additional Workforce Reduction as Part of Previously Announced Corporate Restructuring
9. Halogen Announces Record Year - Company Solidifies Leadership Position, Secures Strategic Wins Over Competition
10. Nektar Appoints Hoyoung Huh, M.D., Ph.D., to Serve on the Companys Board of Directors
11. Alynx, Co. Completes Merger With Medical Device Company MiMedx, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2017)... ... August 21, 2017 , ... MacArthur Sotheby’s International Realty, a ... to announce the first Delos Wellness Signature™ residence in Hawaii is on the ... together with listing agent Kelly Allen, R(S) of Carvill Sotheby’s International Realty located ...
(Date:8/21/2017)... ... August 21, 2017 , ... The team at ... educational webinar, in which attendees will learn about the assembly and topological architecture ... with an overview of the development and validation of new high-quality recombinant monoclonal ...
(Date:8/17/2017)... ... August 17, 2017 , ... CNA ... outlet had provided a research update on Aytu Bioscience and cited promising increases ... According to Soulstring, prescription rates for Natesto® have more than doubled since March ...
(Date:8/16/2017)... Ca (PRWEB) , ... August 16, 2017 , ... ... by changing into a different cell type. Many treatments for specific cancers, such ... prominent example of targeted treatment is androgen deprivation therapy for advanced prostate cancer. ...
Breaking Biology Technology:
(Date:3/30/2017)... 2017  On April 6-7, 2017, Sequencing.com will host ... hackathon at Microsoft,s headquarters in Redmond, ... on developing health and wellness apps that provide a ... Genome is the first hackathon for personal genomics ... companies in the genomics, tech and health industries are ...
(Date:3/29/2017)... , March 29, 2017  higi, the health ... in North America , today announced ... and the acquisition of EveryMove. The new investment and ... set of tools to transform population health activities through ... lifestyle data. higi collects and secures data ...
(Date:3/24/2017)... MILAN , March 24, 2017 The Controller ... Deputy Controller Mr. Abdulla Algeen have received the prestigious international ... Continue Reading ... ... small picture) and Deputy Controller Abdulla Algeen (small picture on the right) ...
Breaking Biology News(10 mins):